Lumida
/VMD
⌘K
Viemed Healthcare Inc

Viemed Healthcare Inc

VMD
$12.15USD↑+0.50%+0.06 today

MARKET CAP

465.8M

P/E (TTM)

32.8x

FWD P/E

22.1x

DAY RANGE

$12 – $12

52W RANGE

$6
$13

AI Summary

Stalk
StalkMedium

VMD remains in a Stage 2 advance with a bullish medium-term bias anchored by a rising 50 and 200 SMA. Short-term price has pulled back into rising EMAs and is oversold, lacking clear acceptance above the 9 and 21 EMA. We recommend stalking for a deeper test of the EMAs or the mid-May swing low support before engaging.

  • ↑Q1 revenue of $75.4M grew 28% YoY, driven by sleep therapy demand.
  • ↑Free cash flow improved to $2.6M vs –$5.7M a year ago.
  • ↓Negative earnings yield indicates stock may be overvalued relative to peers.
Full analysis →

The case for & against

Bull & Bear analysis

Bullish

Viemed Healthcare Inc. (NASDAQ: VMD) is a prominent player in the home healthcare sector, specializing in providing respiratory therapy and home medical equipment. The company focuses heavily on sleep therapy and maternal health services, aiming to leverage its innovative solutions and established patient relationships to capture growing market demand. Viemed stands out for its operational efficiency and commitment to improving patient care, having demonstrated robust growth in various segments, particularly in the rising demand for at-home healthcare solutions.

Bull says

  • ↑Q1 revenue of $75.4M grew 28% YoY, driven by sleep therapy demand.
  • ↑Free cash flow improved to $2.6M vs –$5.7M a year ago.
  • ↑PAP therapy patients rose 57% YoY to ~36k, expanding treatment base.
  • ↑Lehan acquisition enhances maternal health services and diversifies revenues.
  • ↑High balance sheet quality and positive stock momentum support stability.
  • ↑Well-established compliance framework positions Viemed to manage regulatory shifts.

Bear says

  • ↓Negative earnings yield indicates stock may be overvalued relative to peers.
  • ↓Negative analyst revisions suggest downward earnings estimate risk ahead.
  • ↓Elevated short interest highlights bearish sentiment and downside pressure.
  • ↓Competitive bidding in home healthcare could compress future margins.
  • ↓Ongoing compliance updates may disrupt operations and limit near-term growth.
  • ↓Small company size may hinder scalability and competitive positioning.

Investment themes with VMD

Medical Devices↑ +0.44%

Devices and instruments for medical treatment

MEDP · RDNT · OPCH

Earnings Call · Q1 2026 · Mgmt. Guidance

Updated 05-09-2026bullish

Transcript signals

Bull points

  • First quarter revenue was $75.4 million, up 28% over the prior year, demonstrating strong execution across our entire platform and consistent with our communicated plans for the year.
  • Pap therapy patients grew 57% year-over-year, contributing to a larger and steadily expanding base of resupplied patients, which now stands at nearly 36,000, providing greater visibility into future revenue and a more stable growth profile.
  • the early results from our maternal health offerings are exceeding our expectations, with significant growth as we serviced just under 4,000 new patients under BiMed contracts in markets where we previously had no presence.

Bear points

  • the turnover rate for ventilator patients set up under the new NCD criteria is higher than pre-NCD, creating some near-term pressure on the net patient census number, which ended the quarter at 12,089 patients.
Read full transcript analysis ›